Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: An open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteers

Clinical Therapeutics

Volumn 32, Issue 11, 2010, Pages 1968-1976

  Kim, Tae Eun ^a   Kim, Kyu Pyo ^a   Kim, Bo Hyung ^a   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

LBEP0202; Pharmacodynamics; Pharmacokinetics; Recombinant human erythropoietin

Indexed keywords

ERYTHROPOIETIN; LBEP 0202; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; ANKLE SPRAIN; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; EPIGASTRIC DISCOMFORT; HUMAN; INJECTION SITE; MALE; OPEN STUDY; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; RHINORRHEA; SINGLE DRUG DOSE; SOUTH KOREA; VOLUNTEER;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; EPOETIN ALFA; HEMATINICS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; REPUBLIC OF KOREA; RETICULOCYTES; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 78649364413     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.10.001     Document Type: Article

References (17)

1. Caro J Anemia of chronic renal failure. Williams Hematology 2006, McGraw- Hill, Medical Pub. Division, New York, NY, Chapter 35. 7th ed. M.A. Lichtman (Ed.).
2. Kaushansky K, Kipps TJ Hematopoietic agents: Growth factors, minerals, and vitamins. Goodman & Oilman's Manual of Pharmacology and Therapeutics 2008, McGraw-Hill Medical, New York, NY, Chapter 53. 11th ed. L.L. Brunton, K.L. Parker, D.K. Blumenthal, I.L. Buxton (Eds.).
3. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987, 316:73-78.
4. Procrit (epoetin alfa) [package insert] 2008, Amgen Inc, Thousand Oaks, Calif, Accessed December 3, 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103234s5164lbl.pdf.
5. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991, 50:702-712.
6. Ramakrishnan R, Cheung WK, Wacholtz MC, et al. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2004, 44:991-1002.
7. Quantikine IVD Human EPO EIA kit [package insert] 2009, R&D Systems Inc, Minneapolis, Minn, Accessed December 4, 2009. http://www.rndsystems.com/pdf/dep00.pdf.
8. Patterson S, Jones B Bioequivalence and Statistics in Clinical Pharmacology 2006, Chapman & Hall/CRC, Boca Raton, Fla, Chapter 3.
9. Rowland M, Tozer TN Clinical Pharmacokinetics: Concepts and Applications 1995, Lea & Febiger, Philadelphia, Pa, Chapters 4, 6. 3rd ed.
10. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research, Accessed September 27, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf.
11. Togawa A, Tanaka T, Nagashima S, et al. A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection. Br J Clin Pharmacol. 2004, 58:269-276.
12. Cheung WK, Natarajan J, Sanders M, Vercammen E Comparative pharmacokinetics, safety, and tolerability after subcutaneous administration of recombinant human erythropoietin formulated with different stabilizers. Biopharm Drug Dispos. 2000, 21:211-219.
13. Klausen T, Dela F, Hippe E, Galbo H Diurnal variations of serum erythropoietin in trained and untrained subjects. Eur J Appl Physiol Occup Physiol. 1993, 67:545-548.
14. Barrett JS Bioequivalence of biologics. Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development 2006, Wiley-VCH, Weinheim, Germany, Chaper 8. J.S. Barrett (Ed.).
15. Pérez-Oliva JF, Casanova-Gonzalez M, Garcfa-Garcfa I, et al. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on he- modialysis: A parallel, randomized, double blind study. BMC Nephrol. 2005, 6:5. Bioequivalence Study of Erythropoietin Group.
16. Woo S, Jusko WJ Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos. 2007, 35:1672-1678.
17. European Medicines Agency Guide-line on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins. Accessed July 14, 2010. http://www.ema.europa.eu/pdfs/human/biosimilar/30163608enfin.pdf.